Authors: Huang, Ya-Ting PhD, RN, NP∗,†; Chen, Tom Wei-Wu MD, PhD‡,§,∥,¶; Chen, Li-Yu MS∗; Huang, Ya-Yao PhD∗,∗∗; Lu, Yen-Shen MD, PhD
Introduction
18Ffluoroestradiol (FES) can be used for the noninvasive visualization and quantification of tumor estrogen receptor (ER) expression and activity and was FDA-approved as a diagnostic agent in May 2022 for detecting ER-positive lesions in patients with recurrent or metastatic breast cancer. PET imaging was also used to detect ER-positive lesions and malignancy among patients with uterine, ovarian, and other ER-positive solid tumors. We conducted a systemic review of the studies on FES PET imaging used among patients with cancer not limited to breast cancer to better understand the application of FES PET imaging.